Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Radionuclides with alpha emitters plays an important role in treating cancers in the field of therapeutic radiopharmaceuticals. Some properties such as short range and deposited energy in unit length of pathway augment the effect of alpha particle in destroying the DNA of cancer cells. Therefore, recognizing this capacity involves more investigations over the biological effect of these particles on human body. Properties of alpha emitters has led to exert profound differences between this field and other fields of nuclear medicine. Due to their short range and high LET (deposit energy in unit length of their pathway), alpha particles have remarkably been considered into medical research.
Targeted anticancer or alpha therapy (TAT) is gaining popularity with the swelling prevalence of cancer and cardiovascular diseases. Businesses are now increasingly aware of the potential benefits of targeted therapies to treat several chronic ailments. Additionally, radio immunotherapy with short-ranged and high-efficiency ?-particles is a striking and promising treatment approach.
Previously, more effective therapeutic nuclear medicines have been launched, which have shown positive results for the treatment of various types of cancer. For instance, the launch of Xofigo (Radium-223) by Bayer for the treatment of prostate cancer and the launch of Lutathera (Lutetium-177) for the treatment of neuroblastoma and synovitis has created growth opportunities for the therapeutic nuclear medicines market. In addition, the launch of these products has boosted the demand for therapeutic nuclear medicines among patients and physicians as well as opened the door for the other pharmaceutical manufacturers to launch more efficient therapeutic nuclear medicines.
Increase in awareness of the potential benefits of targeted alpha emitter and high number of patients with various types of cancers such as ovarian cancer, pancreatic cancer, lymphoma, and melanoma are likely to augment market growth. In addition, increasing use of targeted anticancer or alpha therapy (TAT) in the treatment of cancer and alpha particles has an advantage in targeted therapy because of their exceptionally high cell-killing ability. Ovarian cancer uses radioimmunotherapy as locally injected adjuvant therapy. Trials have evaluated the practice of complete abdominal or moving-strip external-beam radiotherapy (EBRT) or non-specific i.p. radiotherapy, with colloid preparations of Au-198 or P-32 as adjuvant therapies. Furthermore, a recent Phase I clinical trial involving At-211-MX35 F (ab) showed significant efficacy, as therapeutic doses reached their targets in patients with ovarian cancer.
The healthcare industry has observed a relatively slow growth due to the COVID-19 pandemic unlike other industries. Numerous therapeutic regimens are being followed across the world in efforts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line emphases to use antiviral drugs used in the disease management of HIV. Both these approaches have poured demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be controlled upon.
The global market is studied for the key regions such as, North America, Europe, Asia Pacific and Rest of the World. North America comprises of U.S., Canada and Mexico. Whereas, Europe covers UK, France, Germany, Italy, Spain and Rest of Europe. The key countries included under Asia Pacific are China, India, Japan and Rest of Asia Pacific. The Rest of the world include Latin America and Middle East & Africa. North America was a lucrative region for the alpha emitters market in 2019. North America currently dominates the alpha emitter market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the fact that the increase in cardiac and neurological chronic diseases. For instance, 223RaCl2 (Xofigo) is the first alpha-emitting radioisotope to gain registration in the United States for palliative therapy of prostate cancer bone metastases through indirect physiological targeting.
The report analyses the global alpha emitters market based on radionuclide type, medical application, end user and geography. Various radionuclide type studied are segmented into Actinium (Ac-225), Astatine (At-211), Bismuth (Bi -213), Bismuth (Bi-212), Lead (Pb-212), Radium (Ra-223) and Terbium (Tb-149). Alpha emitter offers many advantages when compared to beta emitters and photon therapy, thus making it an increasingly favoured mode of treatment. As a result, this has caught the attention of key companies interested in capitalizing the market potential.
The medical application segment is categorized into prostate cancer, bone metastases, ovarian cancer, pancreatic cancer, endocrine tumors and others. Alpha emitter therapy holds a great promise when compared to chemotherapy as targeted alpha therapy allows easy discrimination between the healthy cells and cancer cells, and hence are effectively used for treatment of cancers including ovarian cancer, pancreatic cancer etc. Furthermore, the major end users considered in the study are hospitals, clinics and research laboratories.
The key companies in the alpha emitters market are Actinium Pharmaceuticals, Alpha Tau Medical, Bayer AG, IBA RadioPharma Solutions, NTP Radioisotopes, Plexus NSD, Triad Isotopes, Telix Pharmaceuticals Ltd, RadioMedix Inc. and Fusion Pharmaceuticals. Moreover, the leading radiopharmaceutical manufacturers are collaborating with hospitals and cancer research institutes for the sale of their products, which has increased the acceptance of therapeutic nuclear medicines. For instance, in January 2020, Actinium Pharmaceuticals, Inc., entered into an agreement with the University of California to utilize Actinium's Antibody Radiation-Conjugate or ARC apamistamab-I-131 for targeted conditioning and replace the chemotherapy conditioning being used in an ongoing Phase 1/2 stem cell gene therapy clinical trial. In the trial, patients with relapsed or refractory HIV-related lymphoma are being treated with autologous stem cell gene therapy.
The report analyses the global alpha emitters market based on radionuclide type, medical application, end user and geography. Various radionuclide type studied are segmented into Actinium (Ac-225), Astatine (At-211), Bismuth (Bi -213), Bismuth (Bi-212), Lead (Pb-212), Radium (Ra-223) and Terbium (Tb-149). The medical application segment is categorized into prostate cancer, bone metastases, ovarian cancer, pancreatic cancer, endocrine tumors and others. Furthermore, the major end users considered in the study are hospitals, clinics and research laboratories.
The global market is studied for the key regions such as, North America, Europe, Asia Pacific and Rest of the World. North America comprises of U.S., Canada and Mexico. Whereas, Europe covers UK, France, Germany, Italy, Spain and Rest of Europe. The key countries included under Asia Pacific are China, India, Japan and Rest of Asia Pacific. The Rest of the world include Latin America and Middle East & Africa.
Why to buy this report:
